The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)
Il valore di obinutuzumab per il trattamento in prima linea del Linfoma Follicolare: un’analisi basata su approccio Multicriteria Decision Analysis (MCDA)
Introduction: Multicriteria Decision Analysis (MCDA) provides a framework that enhances transparency and repeatability of decisions taken on a multicriteria basis.
Objective: This analysis aims at assessing obinutuzumab compared to rituximab used as a first-line treatment for Follicular Lymphoma (FL) in the Italian health care system, using an MCDA approach.
Materials and Methods: We used the EVIDEM V10 MCDA framework and a Delphi approach to scrutinize the views of a panel of physicians, payers and patients on value domains and their application to our research target.
Results: All stakeholders attached medium-high scores to FL severity (patients at higher risk of relapsing), unmet needs, obinutuzumab clinical benefit and evidence quality, and lower scores to organizational impact and, except for payers, to costs. The comparative analysis highlighted positive scores for the domains “incremental efficacy” (2.6: range −5/+5) and “incremental patient benefit” (1.5: range −5/+5) of obinutuzumab compared to rituximab. A slight increase of severe adverse events (≥3) for obinutuzumab was estimated by the panellists. Obinutuzumab compared to rituximab received a neutral evaluation for costs and for organizational impact.
Conclusion: This study reveals that MCDA could be a useful framework for evaluating a drug and it can be used to elicit the views of different stakeholder groups (as patients). The key criteria driving the value of obinutuzumab.
(HTA & Market Access)
Sussex, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013 Jan;31(1):1-10.
Jommi C. Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries. Global & Regional Health Technology Assessment. 2015;2(3):117-62.
Kolasa K, Zah V, Kowalczyk M. How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):379-91.
Mussen F, Salek S, Walker S. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiol Drug Saf. 2007 Jul;16 Suppl 1:S2-S15.
Goetghebeur MM, Wagner M, Khoury H et al. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Making. 2012 Mar-Apr;32(2):376-88.
Tervonen T, Naci H, van Valkenhoef G et al. Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: choosing among statins in primary prevention. Med Decis Making. 2015 Oct;35(7):859-71.
Marsh K, IJzerman M, Thokala P et al. Multiple criteria decision analysis for health care decision making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016 Mar-Apr;19(2):125-37.
NICE, Obinutuzumab for untreated advanced follicular lymphoma - Technology appraisal guidance [TA513] Published date: 21 March 2018. https://www.nice.org.uk/guidance/ta513/chapter/1-Recommendations (ultimo accesso 14/03/2019).
Marcus R, Davies A, Ando K et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-44.
EVIDEM. EVIDEM Framework 10th Edition. https://www.evidem.org/ (ultimo accesso 26/2/2018 è corretto l’anno??).
Esmé G, Trevelyan J, Robinson C. Delphi methodology in health research: how to do it? Eur J Integr Med. 2015;7(4):423-8.
Garau M, Hampson G, Devlin N et al . Applying a Multicriteria Decision Analysis (MCDA) approach to elicit stakeholders' preferences in Italy: The case of obinutuzumab for rituximab-refractory Indolent Non-Hodgkin Lymphoma (iNHL). Pharmacoecon Open. 2018;2(2):153-63.
Jommi C, Bertolani A. Patient Associations and HTA for medicines: present and future role in Italy. Global & Regional Health Technology Assessment. 2018:1-11.
Ministero della Salute. Documento in materia di governance farmaceutica (http://www.salute.gov.it/imgs/C_17_notizie_3567_listaFile_itemName_0_file.pdf, ultimo accesso 16/4/2019).
Copyright (c) 2019 Claudio Jommi, Roberto Ravasio
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.